clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kelly C et al. Macrolide antibiotics for bronchiectasis. 2018 Cochrane Database Syst Rev pmid:29543980
Yeo YH et al. First-line eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. 2018 Gut pmid:27670375
Suzuki R et al. Sinobronchial syndrome treated as intractable asthma. 2018 Pediatr Int pmid:30320426
Mégraud F Antibiotic Resistance Is the Key Element in Treatment of Helicobacter pylori Infection. 2018 Gastroenterology pmid:30308190
Mieras LF et al. An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+. 2018 BMC Infect. Dis. pmid:30290790
Liou JM et al. Toward population specific and personalized treatment of Helicobacter pylori infection. 2018 J. Biomed. Sci. pmid:30285834
Liu HY et al. Bilateral Non-tuberculous Mycobacterial Keratitis After Small Incision Lenticule Extraction. 2018 J Refract Surg pmid:30199569
Kabakambira JD et al. Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial. 2018 BMC Gastroenterol pmid:30165823
Yotsu RR et al. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). 2018 Cochrane Database Syst Rev pmid:30136733
Abu-Khalaf N et al. The Taste of Commercially Available Clarithromycin Oral Pharmaceutical Suspensions in the Palestinian Market: Electronic Tongue and In Vivo Evaluation. 2018 Sensors (Basel) pmid:29401675
Tanabe H et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. 2018 Ann. Clin. Microbiol. Antimicrob. pmid:29950163
Sandri A et al. Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. 2018 Virulence pmid:29938577
Gonzalez-Hormazabal P et al. Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. 2018 BMC Gastroenterol pmid:29925321
Clarithromycin in patients with coronary artery disease. 2018 Med Lett Drugs Ther pmid:29913468
Li M et al. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. 2018 Helicobacter pmid:29873436
Blümel B et al. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. 2018 Helicobacter pmid:29873430
Ito M et al. Phase transitions of antibiotic clarithromycin forms I, IV and new form VII crystals. 2018 Int J Pharm pmid:29864514
Jin BH et al. Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study. 2018 Eur. J. Clin. Pharmacol. pmid:29846770
Auesomwang C et al. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. 2018 J. Gastroenterol. Hepatol. pmid:29804294
Chai KY et al. Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report. 2018 J Med Case Rep pmid:29743095
Strouvalis I et al. Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence. 2018 Respirology pmid:29741298
Long X et al. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. 2018 Helicobacter pmid:29696736
Fiorini G et al. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016. 2018 Scand. J. Gastroenterol. pmid:29688095
Matta AJ et al. Punctual mutations in gene of clarithromycin-resistant in Colombian populations. 2018 World J. Gastroenterol. pmid:29662291
Rodríguez-Sevilla G et al. Influence of three-dimensional lung epithelial cells and interspecies interactions on antibiotic efficacy against Mycobacterium abscessus and Pseudomonas aeruginosa. 2018 Pathog Dis pmid:29648588
Takemori N et al. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. 2018 J Med Case Rep pmid:29454372
Xu R et al. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. 2018 Eur. J. Clin. Pharmacol. pmid:29453492
Tsutsui A et al. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. 2018 J. Infect. Chemother. pmid:29428566
Tarhini M et al. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. 2018 Microb. Pathog. pmid:29428426
Kobayashi T et al. The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma. 2018 Ann. Hematol. pmid:29427183
Wang S et al. Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. 2018 Water Res. pmid:29426033
Yagbasan A et al. A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. 2018 Niger J Clin Pract pmid:29411724
Maiolino G et al. Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism. 2018 Blood Press. pmid:29409357
Takahashi E et al. Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. 2018 Comp. Immunol. Microbiol. Infect. Dis. pmid:29406285
Wang YH et al. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. 2018 Helicobacter pmid:29405526
Tso S et al. Clarithromycin as a steroid sparing agent for the management of infantile bullous pemphigoid. 2018 BMJ Case Rep pmid:29374651
Sahara S et al. Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. 2018 Digestion pmid:29310119
Sue S et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. 2018 Helicobacter pmid:29271026
Iwamoto J et al. Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease. 2018 Intern. Med. pmid:29093413
Ersoy B et al. The anti-inflammatory effects of erythromycin, clarithromycin, azithromycin and roxithromycin on histamine-induced otitis media with effusion in guinea pigs. 2018 J Laryngol Otol pmid:29888693
Inagaki Y et al. Disseminated Cutaneous Infection of Mycobacterium colombiense in a Patient with Myelodysplastic Syndrome. 2018 Intern. Med. pmid:29093379
De Francesco V et al. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. 2018 Dig Liver Dis pmid:29089267
Cerqueira RM et al. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. 2018 Obes Surg pmid:29076008
Haj Yahia S et al. Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients. 2018 Rheumatol. Int. pmid:28975396
Shaharir SS et al. Non-tuberculous mycobacterium bacteraemia in a pregnant systemic lupus erythematosus (SLE) patient: a case review and pooled case analysis. 2018 Clin. Rheumatol. pmid:28971307
Marsousi N et al. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. 2018 Biopharm Drug Dispos pmid:28960401
Popovic V et al. Mycobacterium shimoidei-cavitary pulmonary disease with favorable outcome. 2018 Folia Microbiol. (Praha) pmid:28913757
Hosono Y et al. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study. 2018 J. Infect. Chemother. pmid:29361415
Sancak S et al. A pioneering study: oral clarithromycin treatment for feeding intolerance in very low birth weight preterm infants. 2018 J. Matern. Fetal. Neonatal. Med. pmid:28279123
Alenezi A et al. Controlled release of clarithromycin from PLGA microspheres enhances bone regeneration in rabbit calvaria defects. 2018 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:28067984